A new Alzheimer’s drug has been approved for use in the United States, but it is unclear whether that should be seen as a cause for celebration or another victory for the pharmaceutical industry in its drive for profits.
The drug, called Aducanumab (to be marketed as Aduhelm), was developed by Biogen and the Japanese drug firm Eisai Co., according to the…
Keep reading with a 7-day free trial
Subscribe to Channel Surfing to keep reading this post and get 7 days of free access to the full post archives.